5 important facts from a recent double-blind, randomized phase 3 study about siponimod in SPMS.
Are you a US-based MD who sees patients with neurologic disorders and who likes to write? Why not blog for NeurologyTimes.com? It's your place to be heard on topics that keep you up at night. Contact us here and we can send you the details.